Fidaxomicin

Restricted
Restricted

C. diff Risk

None

Oral Bioavailability

None

Approximate Cost

Spectrum Of Activity

Dosing

Non-Formulary form must be completed

Restricted to treatment of recurrent or refractory C. difficile colitis in patients who have failed therapy with oral vancomycin

200 mg po BID x 10 days

General Information

Acceptable Uses

Treatment of recurrent or refractory C. difficile colitis in patients who have failed therapy with oral vancomycin

Unacceptable Uses

Treatment of initial C. difficile colitis episode.

Common Usage

C. difficile colitis

Adverse Effects

  • ¬†GI disturbance

  • ¬†Cytopenias

  • ¬†Hypersensitivity: facial, tongue or throat swelling

Additional Information

Consult Infectious Disease

Pharmacology

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Urine penetration: None

Lung penetration: None

CSF penetration: None

Biliary penetration: None